Survival of Mexican-American males with seminoma.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 9294957)

Published in Rev Invest Clin on November 17, 1997

Authors

D Di Domenico1, P Bridges, R Sharifi, M Rubenstein, P Guinan

Author Affiliations

1: Department of Urology, University of Illinois, Chicago, USA.

Articles by these authors

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Urology (1995) 2.83

Carcinoembryonic antigen in patients with different cancers. JAMA (1972) 2.56

Causes, presentation and survival of fifty-seven patients with necrotizing fasciitis of the male genitalia. Surg Gynecol Obstet (1990) 2.31

Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst (2001) 1.47

Genetic linkage of Werner's syndrome to five markers on chromosome 8. Nature (1992) 1.37

Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol (1995) 1.36

Letter: Levulinic esters. An alcohol protecting group applicable to some nucleosides. J Am Chem Soc (1975) 1.31

The effect of estrogen on the incorporation of 3H-thymidine by PHA-stimulated human peripheral blood lymphocytes. J Immunol (1974) 1.21

Involvement of the genitourinary system in multiple primary malignant neoplasms: a review. J Clin Oncol (1983) 1.18

A new look at the saturn system: the voyager 2 images. Science (1982) 1.15

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology (1997) 1.08

Urethral diverticular carcinoma. Cancer (1992) 1.01

Prostate cancer patients' utilities for health states: how it looks depends on where you stand. Med Decis Making (1998) 0.99

Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J Am Coll Surg (1995) 0.98

Overflow urinary incontinence due to carbamazepine. J Urol (1985) 0.97

A comparative follow-up study of inpatient and outpatient psychiatric referrals seen in a general hospital. Compr Psychiatry (1972) 0.95

Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer. Urology (2000) 0.95

The accuracy of the rectal examination in the diagnosis of prostate carcinoma. N Engl J Med (1980) 0.94

In vitro effects of dichloroacetate and CO2 on hypoxic HeLa cells. Anticancer Res (2009) 0.92

Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology (1998) 0.91

Cochlear action potentials in experimentally induced hypothyroidism in guinea pigs. Acta Otolaryngol Suppl (1975) 0.91

Changes in radical prostatectomy and radiation therapy rates for African Americans and whites. J Natl Med Assoc (2000) 0.90

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology (1995) 0.90

Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum Pathol (1996) 0.89

Benign fibrous ureteral polyps. Urology (1987) 0.89

Carcinoembryonic antigen in patients with tumors of the urogenital tract. Cancer (1972) 0.89

Ethanolamine sclerotherapy of a renal cyst. J Urol (1995) 0.89

Periarticular inflammation, bilateral hilar adenopathy and a sarcoid reaction. Arthritis Rheum (1970) 0.89

Successful streptokinase therapy for catheter-induced subclavian vein thrombosis. Arch Intern Med (1980) 0.87

An evaluation of prostate specific antigen in prostatic cancer. J Urol (1987) 0.87

Warfarin resistance and vitamin K. Ann Intern Med (1981) 0.87

Immunobiology of the Dunning R-3327 rat prostate adenocarcinoma sublines: plasma and tumor effusion prostaglandins. Am J Reprod Immunol Microbiol (1985) 0.87

A genetic analysis of the Werner syndrome region on human chromosome 8p. Genomics (1993) 0.87

Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. Urology (1991) 0.87

Renal cell carcinoma: the size variable. J Surg Oncol (1993) 0.86

Chart for preparation of dilutions of alpha-adrenergic agonists for intracavernous use in treatment of priapism. J Urol (1995) 0.86

Prostate cancer: the stage disadvantage in the black male. J Natl Med Assoc (1991) 0.85

Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology (1982) 0.85

Effect of piperacillin on tobramycin pharmacokinetics in patients with normal renal function. Antimicrob Agents Chemother (1983) 0.85

Multiple primary tumors in a 72-year-old woman. J Urol (1983) 0.85

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer (1996) 0.85

Immunosuppressive effects of antimacrophage serum and antithymocyte serum on mouse skin allografts. J Med (1972) 0.84

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. Prostate (1999) 0.84

Lipofuscin granules in normal, benign and malignant human prostatic tissue. Urol Res (1973) 0.84

Safety and efficacy of intravesical aminocaproic acid for bleeding after transurethral resection of prostate. Urology (1986) 0.84

In vivo establishment of T98G human glioblastoma. Methods Find Exp Clin Pharmacol (1999) 0.84

Solitary renal calix. JAMA (1978) 0.83

An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer. J Surg Oncol (1998) 0.82

Humoral hypercalcemia due to squamous cell carcinoma of renal pelvis. Urology (1988) 0.82

A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians. Eur Urol (1997) 0.82

Contemporary indications for psychosurgery. Br J Psychiatry (1981) 0.82

Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. J Clin Oncol (1987) 0.81

Prostate cancer and the multiple primary malignant neoplasm syndrome. Prostate (1983) 0.81

Stage IV renal cell carcinoma. J Urol (1994) 0.81

The proliferative response of hela cells to 2-deoxy-D-glucose under hypoxic or anoxic conditions: an analogue for studying some properties of in vivo solid cancers. Anticancer Res (2007) 0.81

An evaluation of five tests to diagnose prostate cancer. Prog Clin Biol Res (1987) 0.81

Prognostic value of cell surface antigens using immunoperoxidase methods in bladder carcinoma. Urology (1982) 0.81

Evaluation of cytologic techniques for diagnosis of prostate cancer. Urology (1983) 0.81

Spouse ratings of quality of life in patients with metastatic prostate cancer of lower socioeconomic status: an assessment of feasibility, reliability, and validity. Urology (2001) 0.81

Condyloma acuminatum in a 2 1/2-year-old girl. J Urol (1983) 0.81

Malacoplakia of the prostate. South Med J (1977) 0.81

Effects of sex steroids on cell growth and C-myc oncogene expression in LN-CaP and DU-145 prostatic carcinoma cell lines. Int Urol Nephrol (1995) 0.81

Report of 337 patients with renal cell carcinoma emphasizing 110 with stage IV disease and review of the literature. J Surg Oncol (1997) 0.81

Comparison of ciprofloxacin and beta-lactam antibiotics in the treatment of urinary tract infections and alteration of fecal flora. Am J Med (1987) 0.80

Carcinoembryonic antigen in the diagnosis of prostate carcinoma. Oncology (1974) 0.80

Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol (1996) 0.80

Bone scan as a stratification variable in advanced prostate cancer. Cancer (1991) 0.80

Decreased survival of black Americans with testicular cancer. J Urol (1998) 0.80

Lymphocele formation after extraperitoneal pelvic lymphadenectomy: possible predisposing factors. J Urol (1986) 0.80

Massive scrotal and occult preputial metastases from carcinoma of the prostate. Br J Urol (1978) 0.79

A multi-attribute model of prostate cancer patient's preferences for health states. Qual Life Res (1999) 0.79

Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model. Methods Find Exp Clin Pharmacol (1998) 0.79

Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivation. Med Oncol (1997) 0.79

Quality of life in low-income patients with metastatic prostate cancer: divergent and convergent validity of three instruments. Qual Life Res (1999) 0.79

A qualitative analysis of acidic proteins associated with regressing, growing, or dividing rat ventral prostate cells. Prostate (1983) 0.79

An immunohistologic characterization of human prostatic atypical hyperplasia. Urol Res (1990) 0.79

Application of immunohistologic staining to develop a malignant index to aid in distinguishing benign from malignant prostatic tissue. Prostate (1989) 0.79

Combination therapy using polyamine synthesis inhibitor alpha-difluoromethylornithine and adriamycin in treatment of rats carrying the Dunning R3327 MAT-LyLu prostatic adenocarcinoma. Prostate (1987) 0.79

Retinal artery changes correlated with other hypertensive parameters in a coronary heart disease case-history study. Br Heart J (1968) 0.79

Ultrasonic imaging during renal surgery for calculi. J Belge Radiol (1986) 0.79

Normoxic or hypoxic CD44/CD41 a₂ B₁ integrin-positive prostate PC3 cell side fractions and cancer stem cells. Med Oncol (2013) 0.79

Adipose tissue growth patterns during human gestation: a histometric comparison of buccal and gluteal fat depots. Int J Obes (1985) 0.79

Immunosuppressive effect of estrogen on thymic dependent lymphocytic blastogenesis. Urol Res (1974) 0.78

The effect of androgen deprivation on malignant and benign prostate tissue. Med Oncol (1998) 0.78